[1] Brewer HB Jr, Lux SE, Ronan R, et al. Amino acid sequence of human apoLp-Gln-Ⅱ (apoA-Ⅱ), an apolipoprotein isolated from the high-density lipoprotein complex[J]. Proc Natl Acad Sci USA, 1972, 69(5): 1304–1308. doi:  10.1073/pnas.69.5.1304
[2] Pownall HJ, Gillard BK, Gotto AM Jr. Setting the course for apoAⅡ: a port in sight?[J]. Clin Lipidol, 2013, 8(5): 551–560. doi:  10.2217/clp.13.59
[3] Borghini I, Barja F, Pometta D, et al. Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid[J]. Biochim Biophys Acta, 1995, 1255(2): 192–200. doi:  10.1016/0005-2760(94)00232-N
[4] Warden CH, Hedrick CC, Qiao JH, et al. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-Ⅱ[J]. Science, 1993, 261(5120): 469–472. doi:  10.1126/science.8332912
[5] van't Hooft FM, Ruotolo G, Boquist S, et al. Human evidence that the apolipoprotein A-Ⅱ gene is implicated in visceral fat accumulation and metabolism of triglyceride-rich lipoproteins[J]. Circulation, 2001, 104(11): 1223–1228. doi:  10.1161/hc3601.095709
[6] Gordon SM, Chung JH, Playford MP, et al. High density lipoprotein proteome is associated with cardiovascular risk factors and atherosclerosis burden as evaluated by coronary CT angiography[J]. Atherosclerosis, 2018, 278: 278–285. doi:  10.1016/j.atherosclerosis.2018.09.032
[7] Constantinou C, Karavia EA, Xepapadaki E, et al. Advances in high-density lipoprotein physiology: surprises, overturns, and promises[J]. Am J Physiol Endocrinol Metab, 2016, 310(1): E1–E14. doi:  10.1152/ajpendo.00429.2015
[8] Tsompanidi EM, Brinkmeier MS, Fotiadou EH, et al. HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis[J]. Atherosclerosis, 2010, 208(1): 3–9. doi:  10.1016/j.atherosclerosis.2009.05.034
[9] Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events[J]. N Engl J Med, 2007, 357(21): 2109–2122. doi:  10.1056/NEJMoa0706628
[10] Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome[J]. N Engl J Med, 2012, 367(22): 2089–2099. doi:  10.1056/NEJMoa1206797
[11] Lincoff AM, Nicholls SJ, Riesmeyer JS, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease[J]. N Engl J Med, 2017, 376(20): 1933–1942. doi:  10.1056/NEJMoa1609581
[12] The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy[J]. N Engl J Med, 2011, 365(24): 2255–2267. doi:  10.1056/NEJMoa1107579
[13] The HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients[J]. N Engl J Med, 2014, 371(3): 203–212. doi:  10.1056/NEJMoa1300955
[14] Bowe B, Xie Y, Xian H, et al. High density lipoprotein cholesterol and the risk of all-cause mortality among U.S. Veterans[J]. Clin J Am Soc Nephrol, 2016, 11(10): 1784–1793. doi:  10.2215/CJN.00730116
[15] Loscalzo J. Molecular mechanisms of atherosclerosis[M]. London: CRC Press, 2004: 111–174.
[16] Kavo AE, Rallidis LS, Sakellaropoulos GC, et al. Qualitative characteristics of HDL in young patients of an acute myocardial infarction[J]. Atherosclerosis, 2012, 220(1): 257–264. doi:  10.1016/j.atherosclerosis.2011.10.017
[17] Filou S, Lhomme M, Karavia EA, et al. Distinct roles of apolipoproteins A1 and E in the modulation of high-density lipoprotein composition and function[J]. Biochemistry, 2016, 55(27): 3752–3762. doi:  10.1021/acs.biochem.6b00389
[18] Zvintzou E, Lhomme M, Chasapi S, et al. Pleiotropic effects of apolipoprotein C3 on HDL functionality and adipose tissue metabolic activity[J]. J Lipid Res, 2017, 58(9): 1869–1883. doi:  10.1194/jlr.M077925
[19] Pamir N, Pan C, Plubell DL, et al. Genetic control of the mouse HDL proteome defines HDL traits, function, and heterogeneity[J]. J Lipid Res, 2019, 60(3): 594–608. doi:  10.1194/jlr.M090555
[20] Kontush A, Lindahl M, Lhomme M, et al. Structure of HDL: particle subclasses and molecular components[M]//von Eckardstein A, Kardassis D. High density lipoproteins. Cham: Springer, 2015: 3–51.
[21] Boyce G, Button E, Soo S, et al. The pleiotropic vasoprotective functions of high density lipoproteins (HDL)[J]. J Biomed Res, 2018, 32(3): 164–182.
[22] Kypreos KE. ABCA1 promotes the de novo biogenesis of apolipoprotein CⅢ-containing HDL particles in vivo and modulates the severity of apolipoprotein CⅢ-induced hypertriglyceridemia[J]. Biochemistry, 2008, 47(39): 10491–10502. doi:  10.1021/bi801249c
[23] Constantinou C, Mpatsoulis D, Natsos A, et al. The low density lipoprotein receptor modulates the effects of hypogonadism on diet-induced obesity and related metabolic perturbations[J]. J Lipid Res, 2014, 55(7): 1434–1447. doi:  10.1194/jlr.M050047
[24] Tselepis AD, Dentan C, Karabina SAP, et al. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme[J]. Arterioscler Thromb Vasc Biol, 1995, 15(10): 1764–1773. doi:  10.1161/01.ATV.15.10.1764
[25] Kelesidis T, Currier JS, Huynh D, et al. A biochemical fluorometric method for assessing the oxidative properties of HDL[J]. J Lipid Res, 2011, 52(12): 2341–2351. doi:  10.1194/jlr.D018937
[26] Knott TJ, Priestley LM, Urdea M, et al. Isolation and characterisation of a cDNA encoding the precursor for human apolipoprotein AⅡ[J]. Biochem Biophys Res Commun, 1984, 120(3): 734–740. doi:  10.1016/S0006-291X(84)80168-0
[27] Petropoulou PI, Berbée JFP, Theodoropoulos V, et al. Lack of LCAT reduces the LPS-neutralizing capacity of HDL and enhances LPS-induced inflammation in mice[J]. Biochim Biophys Acta, 2015, 1852(10): 2106–2115. doi:  10.1016/j.bbadis.2015.07.010
[28] Rensen PCN, van Berkel TJC. Apolipoprotein E effectively inhibits lipoprotein lipase-mediated lipolysis of chylomicron-like triglyceride-rich lipid emulsions in vitro and in vivo[J]. J Biol Chem, 1996, 271(25): 14791–14799. doi:  10.1074/jbc.271.25.14791
[29] Larsson M, Allan CM, Jung RS, et al. Apolipoprotein C-III inhibits triglyceride hydrolysis by GPIHBP1-bound LPL[J]. J Lipid Res, 2017, 58(9): 1893–1902. doi:  10.1194/jlr.M078220
[30] Kypreos KE, Van Dijk KW, Havekes LM, et al. Generation of a recombinant apolipoprotein E variant with improved biological functions: hydrophobic residues (LEU-261, TRP-264, PHE-265, LEU-268, VAL-269) of apoE can account for the apoE-induced hypertriglyceridemia[J]. J Biol Chem, 2005, 280(8): 6276–6284. doi:  10.1074/jbc.M413458200
[31] Julve J, Escolà-Gil JC, Rotllan N, et al. Human apolipoprotein A-Ⅱ determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome[J]. Arterioscler Thromb Vasc Biol, 2010, 30(2): 232–238. doi:  10.1161/ATVBAHA.109.198226
[32] Marzal-Casacuberta A, Blanco-Vaca F, Ishida BY, et al. Functional lecithin: cholesterol acyltransferase deficiency and high density lipoprotein deficiency in transgenic mice overexpressing human apolipoprotein A-Ⅱ[J]. J Biol Chem, 1996, 271(12): 6720–6728. doi:  10.1074/jbc.271.12.6720
[33] Rosenson RS, Stafforini DM. Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2[J]. J Lipid Res, 2012, 53(9): 1767–1782. doi:  10.1194/jlr.R024190
[34] Flachs P, Rossmeisl M, Kuda O, et al. Stimulation of mitochondrial oxidative capacity in white fat independent of UCP1: a key to lean phenotype[J]. Biochim Biophys Acta, 2013, 1831(5): 986–1003. doi:  10.1016/j.bbalip.2013.02.003
[35] Castellani LW, Goto AM, Lusis AJ. Studies with apolipoprotein A-Ⅱ transgenic mice indicate a role for HDLs in adiposity and insulin resistance[J]. Diabetes, 2001, 50(3): 643–651. doi:  10.2337/diabetes.50.3.643